Commentary on "Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study"

The totality of evidence favors the efficacy of convalescent plasma to treat COVID-19 when high-titer plasma is administered early in the course of disease or to immunocompromised patients. In this commentary, we frame the findings of L. A. Bartelt, A. J. Markmann, B. Nelson, J. Keys, et al. (mBio 1...

Full description

Saved in:
Bibliographic Details
Published inmBio Vol. 13; no. 6; p. e0265322
Main Authors Joyner, Michael J, Paneth, Nigel
Format Journal Article
LanguageEnglish
Published United States American Society for Microbiology 20.12.2022
Subjects
Antibodies, Neutralizing
Antibodies, Viral
Commentary
COVID-19
COVID-19 Serotherapy
Humans
Immunization, Passive
SARS-CoV-2
Online AccessGet full text

Cover

More Information
Summary:The totality of evidence favors the efficacy of convalescent plasma to treat COVID-19 when high-titer plasma is administered early in the course of disease or to immunocompromised patients. In this commentary, we frame the findings of L. A. Bartelt, A. J. Markmann, B. Nelson, J. Keys, et al. (mBio 13:e01751-22, 2022, https://doi.org/10.1128/mBio.01751-22) in the context of the normal approval process for a therapeutic product. We point out that convalescent plasma has taken all of the typical steps associated with approval for a therapeutic product. Additionally, in less than 3 years, the optimal use cases and continued utility of this product to treat COVID-19 have been defined.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Commentary-3
content type line 23
The authors declare no conflict of interest.
ISSN:2150-7511
2150-7511
DOI:10.1128/mbio.02653-22